Carlos Gallardo
Bradford Hill Clinical Research Center
Santiago, RM, Chile
Santiago, RM, Chile
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
Journal: NPJ breast cancer
Published: December 15, 2025
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 24, 2025
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Journal: Nature medicine
Published: May 08, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 21, 2024
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Journal: Journal of the National Cancer Institute
Published: July 12, 2023
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: July 20, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Journal: Nature
Published: October 22, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 30, 2021
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Journal: Ecancermedicalscience
Published: July 26, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: June 26, 2020
Triple-negative breast cancer: the reality in Chile and in Latin America.
Journal: Ecancermedicalscience
Published: May 06, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026